[ADVERT]
Share Name Share Symbol Market Type Share ISIN Share Description
N4 Pharma Plc LSE:N4P London Ordinary Share GB00BYW8QM32 ORD 0.4P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 7.80 7.60 8.00 7.80 7.80 7.80 193,248 07:42:08
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -1.6 -1.0 - 12

N4 Pharma Share Discussion Threads

Showing 8151 to 8174 of 8175 messages
Chat Pages: 327  326  325  324  323  322  321  320  319  318  317  316  Older
DateSubjectAuthorDiscuss
24/9/2021
14:45
I can confirm this is true.
peaky01
24/9/2021
14:41
Nobbygnome has invested in SYME
charlescharliesback
22/9/2021
14:12
Picked up a few late morning; didn't get the very bottom but rude not to, I felt!!!
davethechef
21/9/2021
23:40
Have you tried the telegram chat? The link is in Twitter and it is very informative about Patents and timescales etc etc
bayley100
20/9/2021
08:50
No specific mention of the US patent so hopefully not too far away. Am I missing something here? All of the recent trials have show improvements over dosage and the fact the tablets can be stored at room temperature. I appreciate human trials can show up different issues but why is the market not getting more excited about this one?
alloa2003
20/9/2021
08:39
One would think that the us patent has to be near by now.
janestone
20/9/2021
08:37
All ok but nothing to get excited about in near term. Will keep on watchlist
blueblood
20/9/2021
07:06
Just confirming what we already know:- N4 Pharma Plc ("N4 Pharma" or the "Company") Interim Results N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for vaccines and cancer treatments, announces its unaudited interim results for the six months ended 30 June 2021. Highlights: · Continued strategy to focus on three work streams: optimisation; in vivo studies; and other applications · Key focus on establishing collaborations with a view to securing future commercial agreements, resulting in two Material Transfer Agreements ("MTAs") to assess how well Nuvec® can bind and be optimised for transfection with each respective party's proprietary plasmid: o the first of which operates in the gene therapy space o the second is a pharmaceutical company developing its own proprietary vaccine for Covid-19 using a DNA plasmid · Continued work with Nanomerics on the use of Nuvec® in respect of the delivery of TNFalpha in the treatment of cancer, the initial pilot study to assess the tolerance of different doses has been successful · Pilot studies indicated that a lower dose of 10ug pOVA bound to optimised, monodispersed Nuvec® gave a better result than a 50ug dose of the original, agglomerated Nuvec® used in previous studies · Notifications of intention to grant patents from the European, Australian, and Japanese patent offices o Further strengthening the IP position around Nuvec® with the European Patent Office intention to grant a divisional patent in respect of composition · Contracted through Medicines Discovery Catapult ("Catapult") a full-time Postdoctoral Researcher · Operating loss for the period was £970,628 (30 June 2020: £585,066) · Cash balance at period end of approximately £2.54 million Nigel Theobald, Chief Executive Officer of N4 Pharma Plc, commented: "The first six months of the year has seen an acceleration in our understanding of the capabilities of Nuvec® following our optimisation work. This has been coupled with our first MTAs which, in turn and together with results elsewhere, led us to review the scope of the recently commenced in vivo work with Evotec pushing some of this work into the second half of this financial year. "Our strategy remains the same as it always has and that is to generate sufficient proof of concept data with a view to attracting large pharma and biotech partners to enter into collaborations to explore using Nuvec® as their chosen delivery system. The issues facing mRNA Covid vaccines in respect of storage and distribution are well known following the Coronavirus pandemic. DNA vaccines are more stable than mRNA yet need to use a much higher dose due to the delivery systems currently chosen. Demonstrating suitable efficacy whilst addressing the storage and dosage issues would, we believe, greatly enhance Nuvec® as a potential delivery tool for vaccines in the eyes of collaborators. "With the short-term work programmes likely to provide plenty of data points over the next three to six months coupled with the ongoing MTA work we remain cautiously optimistic as we seek to commercialise Nuvec®. We continue to be well funded for all existing work streams and look forward to analysing the results of studies and sharing them with interested parties when they become available."
alloa2003
15/9/2021
11:23
Back into this one, think the reaction to the good news was muted to say the least. I appreciate the jam tomorrow comments but so far so good. The tablet form of the covid vaccine is showing improvements over refrigerated methods. Even if it was on a par, the fact it doesnt need to be kept in a fridge is a huge benefit. That it seems to work better must be positive?
alloa2003
14/9/2021
12:26
Possible Oral covid vaccine on the distant horizon?Or am I making 2+2= 8345 :-)
tp6
14/9/2021
11:11
Has it gone in humans yet? There is significant risk until this happens....
nobbygnome
14/9/2021
10:42
More jam tomorrow. Will be back in couple of months to take fresh look but out for now. Good luck to all LTHs
blueblood
14/9/2021
07:23
Interesting that the in vivo tests are happening in the same time frame as Pzizer and Merck's in vivo covid tablet tests. I'm speculating, with my fingers crossed.
janestone
14/9/2021
07:21
More great news …
jakleeds
14/9/2021
07:03
RNS Number : 6273L N4 Pharma PLC 14 September 2021 14 September 2021 N4 Pharma plc ("N4 Pharma" or the "Company") Operations Update N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec(R), a novel delivery system for cancer treatments and vaccines, is pleased to provide a further update on its current in vivo work streams due to commence shortly with Evotec. As announced on 24 August 2021, the Company has now successfully completed the amplification and initial testing of a new SARS-COV-2 plasmid at Evotec and finalised the scope of the in vivo study. The first step in this new study was to test the in vitro performance of the new plasmid. The optimised Nuvec(R), together with the new SARS-COV-2 plasmid has demonstrated an improved response in terms of transfection and SARS-COV-2 Spike protein secretion in HEK 293 cells, a commonly used human cell line. In addition, the Nuvec(R)/SARS-COV-2 DNA complex demonstrated a dose-related SARS-COV-2 Spike protein production. These in vitro results provide a positive platform for the commencement of the in vivo work beginning this month which is expected to last six to eight weeks with an additional two to three weeks for analysis. Nanomerics's wider in vivo study, as announced on 20 May 2021, has now validated the results seen from their earlier pilot study, showing an improvement through the use of newly formulated and dried Nuvec(R). The findings of this work will now be adopted in all future work undertaken to ensure all studies are performed using well dispersed Nuvec(R) formulations. Nigel Theobald, Chief Executive Officer of the Company, commented: "The Board is very pleased with these initial in vitro results from the new SARS-COV-2 plasmid which confirms Nuvec(R) is capable of producing results in this area and demonstrate a material improvement on previous results with an earlier plasmid. "We are very excited to commence the in vivo work using this SARS-COV-2 plasmid alongside the MTA (Material Transfer Agreement) work already in place with a potential partner in this area. The aim of the study is to demonstrate the potential of using Nuvec(R) to develop plasmid DNA vaccines using much lower doses than those already approved or are in development and also not requiring refrigeration."
david gruen
25/8/2021
10:36
Everything takes forever with N4P but the groundwork has been done and real results going to be unveiled over next few months
blueblood
24/8/2021
07:54
Whatever you think of this announcement, it reduces the risk factor associated with the company. The market cap of £16m is buttons compared to the potential.
alloa2003
24/8/2021
07:32
All good so far.......interesting to see how shares do first thing
alloa2003
24/8/2021
07:31
24/08/2021 7:00am UK Regulatory (RNS & others) Tuesday 24 August 2021 Operations Update N4 Pharma plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec(R), a novel delivery system for cancer treatments and vaccines, is pleased to provide an update on its current work streams. Collaborations As announced on 20 May 2021, the Company has been working on two Material Transfer Agreements ("MTAs") to assess how well Nuvec(R) can bind and be optimised for transfection with two different proprietary nucleic acid products. The first agreement is with a major international company working in the gene therapy space and the second is with a UK based pharmaceutical company developing its its own proprietary vaccine for Covid-19 using a DNA plasmid. Both projects have progressed well and in each case the Company has been able to successfully load and well disperse Nuvec(R) with the proprietary products at different doses. This will allow the testing of a wide range of options with the MTA partners and each company is now undertaking its own tests with Nuvec(R) and their respective products. Timing of such work will be dependent on each party but the Company remains in regular contact whilst the work continues. In vivo studies As announced on 20 May 2021, the Company received good results from the in vivo pilot dosage study undertaken by Nanomerics using an OVA plasmid. As a consequence of this study, and the work being undertaken under the MTA in respect of a plasmid DNA for Covid-19, the Company took the opportunity to review the scope of the in vivo work planned at Evotec and to assess other Covid-19 plasmid DNAs for use with Nuvec(R). The Company has now successfully completed the amplification and initial testing of a new Covid-19 plasmid at Evotec and finalised the scope of the in vivo study. This proof of concept study is now scheduled to start around the middle of September and is expected to last approximately three months. Dosage follow-on study Nanomerics' wider in vivo study will seek to validate the results seen from the pilot dosage study which, if consistent, would demonstrate a significant improvement through the use of this newly formulated Nuvec(R). This follows 18 months of optimisation and formulation work which has been finalised. Analysis is ongoing and expected to be completed next month. In addition to the work above, Nanomerics has been working with Nuvec(R) in respect of the delivery of TNFalpha in the treatment of cancer. The initial pilot study to assess the tolerance of different doses has been concluded successfully and the second pilot study looking at tumour models will commence shortly and conclude around the end of next month. After this, the main study will begin and take a further ten weeks including analysis at which time the Company will provide an update. Other studies At Medicines Discovery Catapult the Company is undertaking studies to analyse how Nuvec(R) behaves with mRNA both in vitro (binding, dispersion, stability) and in vivo after subcutaneous injection. Finally, in conjunction with the University of Queensland, following the receipt of a grant from the Australian Government, the Company is to commence a more substantive study into the oral application of Nuvec(R). This will be a three-year programme and is fully funded under the grant. Nigel Theobald, Chief Executive Officer of the Company, commented: "It has been a busy and productive period for the Company across our different work streams. All studies have progressed well to the point where we now have visible timelines for their conclusion throughout the fourth quarter of this year and I look forward to providing further updates as and when we are able."
alancapone
24/8/2021
07:18
FOMO should see a good rise in share price at opening. IMHO
pwal
24/8/2021
07:05
Lovely jubbly :-)
jakleeds
23/8/2021
16:32
Bit better today!
blueblood
23/8/2021
09:24
We should get the interim some time in Sept. (last year 17th) so hopefully some good news then.
pwal
21/8/2021
10:15
Takes 6-8 months blueblood for full grant, I’d say we’re nearly at the six month stage, they RNSd it early February I believe. We await US intention to grant that allegedly is in the final stages, that’s a big one for us.
featherby81
Chat Pages: 327  326  325  324  323  322  321  320  319  318  317  316  Older
ADVFN Advertorial
Your Recent History
LSE
N4P
N4 Pharma
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210927 11:29:02